Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD...
-
Upload
emery-carson -
Category
Documents
-
view
222 -
download
0
Transcript of Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD...
![Page 1: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/1.jpg)
Monitoring the Progress of Trials and the Safety of Participants
Don Workman, PhD Victor Santana, MD
St. Jude Children’s Research Hospital
![Page 2: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/2.jpg)
A continuous ongoing review of the conduct of the trial
Shared responsibility
– Research Team/Principal Investigator
– Institutional Officials
– Oversight Committees (IRB, DSMB)
Monitoring the Progress of Trials and the Safety of Participants
![Page 3: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/3.jpg)
Partnership in Research
Investigator
IRBInstitutionalOfficials
Participant
![Page 4: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/4.jpg)
A Systematic Approach to the Problem
Defining what needs to be monitored and reported
Defining role of DSMB and role of IRB
Developing infrastructure to report, evaluate and act upon safety concerns in a timely fashion
![Page 5: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/5.jpg)
Monitoring Elements as Summarized in the NCI Clinical Data Update System
Patient-Specific Data – demographics – treatment status (received therapy)
– date of entry – off-therapy reason(s) subgroup on protocol
– eligibility – performance status
– prior therapy – disease code (diagnosis, SNOMED) treatment by course
– Course ID – Start date
– Rx assignment (ph I) – BSA or weight dose of agent
– agent – dose modification – total dose/course adverse even reporting
– type – grade
– attribution – reporting response
– evaluable – best response at time of evaluation
![Page 6: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/6.jpg)
Monitoring Type or Phase
of TrialMonitoring
Interval
Reports to Subcommittee
Number of Patients to be Monitored
Phase I Central Elements Continuously
Missing Data Reports Monthly
Quarterly First 3 patients enrolled, plus 1 patient per dose level
Phase II Eligibility and Consents Continuously
Central Elements Quarterly
Missing Data Reports Quarterly*
AEs Quarterly
Response coding semiannually, or at appropriate protocol time points
Semiannually, or
as required in the protocol
First 2 patients enrolled, plus at least 10% of total patients accrued
![Page 7: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/7.jpg)
Monitoring Type or Phase
of TrialMonitoring
Interval
Reports to Subcommittee
Number of Patients to be Monitored
Phase III Eligibility and Consents Continuously
Central Elements Quarterly
Missing Data Reports Quarterly*
Response coding semiannually
Other primary objectives
Annually
Semiannually, or
as required in the protocol DSMP
First 2 patients enrolled, plus at least 10% of total patients accrued
ST JUDE holds
IND/IDE
Per study-specific monitoring plan Per study phase Per study phase, or study-specific monitoring plan
![Page 8: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/8.jpg)
The Problem of AE/SAE Reporting and IRB Review
Problems in reporting:
– Over-reporting (reporting of anticipated adverse events)
– Increased research in drugs and biologics
– Increased federal scrutiny—OHRP, FDA
– Saturation effects
– Lack of denominators in Safety Reports, lack of normative data for population under study
![Page 9: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/9.jpg)
The Problem of AE/SAE Reporting and IRB Review
Problems in review:
– External events reports often sketchy summaries—no opportunity for questions/clarifications
– IRB is not DMC/DSMB
– IRB is not FDA with single IND file
– IRB needs to rely on local investigator to interpret the meaning of the events reported
![Page 10: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/10.jpg)
PI Reports & Categorizes Adverse
Events
Electronic SubmissionElectronic Submission
IRBOffice of
RA
Office of VP Clinical Trials
External Reporting:
OHRP
CTEP
NIH
FDA
RAC
SPONSORS
Internal Reporting
Other Committees Institutional
(DSMB, CPSRMC)
FeedbackFeedback
Follow-up
![Page 11: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/11.jpg)
An Intranet-Based Solution for Collecting and Processing AE/SAE/UPIRSOs
Project Development– 18 months from design to implementation – Began with Implementation of a Form, designed
like screen-shots to include checkboxes and fill-in the blanks
– Development of flow-diagram for Web-based Reporter
– Security versus Access issues– Need for electronic “signature” other title 11
issues
![Page 12: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/12.jpg)
An Intranet-Based Solution for Collecting and Processing AE/SAE/UPIRSOs
Project Development– Integration with existing databases
Verifiable identities/access list
Internal reports: subjects/medical record numbers– Links to registered protocols– Information stream to other PIs
External reports: radio buttons for selecting protocol(s) for reporting of events (sometimes multiple studies on single safety report)– E-mail notification to PIs
![Page 13: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/13.jpg)
An Intranet-Based Solution for Collecting and Processing AE/SAE/UPIRSOs
Functional Outcomes
– Real-time IRB reporting: time stamping
– Forced choice, smart forms, no incomplete submissions
– Ease of access—any system signed onto intranet
– Ability to generate single-incident reports
– Ability to generate reports entered in specified time period
![Page 14: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/14.jpg)
An Intranet-Based Solution for Collecting and Processing AE/SAE/UPIRSOs
Functional Outcomes
– Quicker reporting times
– Ability of IRB Office to generate reports based on protocols, type of events, across subjects
– Able to generate internal denominators
– Use of standardized NCI toxicity tables
– Able to record IRB actions, and updates from Investigators onto previous reports
![Page 15: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/15.jpg)
An Intranet-Based Solution for Collecting and Processing AE/SAE/UPIRSOs
Process Improvements
– More timely reporting—able to demonstrate overall compliance
– Better communication between investigators and IRB
– Able to manipulate information into reports
– Improved information summary presentation for reviewers
– Easy access to history of events on any protocol
![Page 16: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/16.jpg)
An Intranet-Based Solution for Collecting and Processing AE/SAE/UPIRSOs
Process Improvements– No need for generating additional
correspondence – PI can generate time-stamped “receipt” by IRB
and determinations from the Committee– Requires PI input on judgments re. Seriousness,
relationship (related/not related), and expected/unexpected
– Requires PI judgments regarding need for revision/amendment to consent/protocol
![Page 17: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/17.jpg)
DEMONSTRATION
![Page 18: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/18.jpg)
![Page 19: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/19.jpg)
![Page 20: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/20.jpg)
![Page 21: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/21.jpg)
![Page 22: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/22.jpg)
![Page 23: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/23.jpg)
![Page 24: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/24.jpg)
![Page 25: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/25.jpg)
![Page 26: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/26.jpg)
Dr Teddy Bear
![Page 27: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/27.jpg)
![Page 28: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/28.jpg)
![Page 29: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/29.jpg)
Conclusions
Technology can be used to improve process for collection and review of information regarding adverse events
Web-based applications can facilitate cross-talk between various databases
Well-designed systems may allow for a single report in an inpatient hospital to generate incident reports, ADR reports, medwatch reports, and AE/Safety reports
![Page 30: Monitoring the Progress of Trials and the Safety of Participants Don Workman, PhD Victor Santana, MD St. Jude Children’s Research Hospital.](https://reader034.fdocuments.net/reader034/viewer/2022051315/56649e745503460f94b74749/html5/thumbnails/30.jpg)
Acknowledgments
Don Workman, Ph.D., IRB Administrator (2003) Donna Hogan, IRB Office, CIP Mickey Weeks, Clinical Informatics Donald Sanderlin, Clinical Informatics Victor Santana, M.D